Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264134 · ClinicalTrials.gov registry record · Phase 1
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Kentuckiana Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00264134 is a Phase 1 study that was terminated before completion, run by Kentuckiana Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00264134, a Phase 1 study, was terminated before completion, sponsored by Kentuckiana Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264134
The ClinicalTrials.gov registry entry for NCT00264134 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kentuckiana Cancer Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00264134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264134 about?
NCT00264134 is a clinical study titled "Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer". Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
What is the current status of trial NCT00264134?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00264134?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00264134?
This trial is sponsored by Kentuckiana Cancer Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.